Clinical trial
A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies
NCT00162500 · Hadassah Medical Organization, Other · Withdrawn
Key facts
| NCT number | NCT00162500 |
|---|---|
| Title | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies |
| Official title | A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies |
| Lead sponsor | Hadassah Medical Organization, Other |
| Collaborators | Vaxil Therapeutics Ltd. Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma, Tumors |
| Intervention type | Biological |
| Interventions | Peptide Vaccine (MUC-1) |
| Enrollment | 15 |
| First posted | Sep 13, 2005 |
| Last update posted | Nov 10, 2010 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: